Drospirenone
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Drospirenone
| |
| Systematic (IUPAC) name | |
| (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)- 1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16- hexadecahydro-10,13-dimethylspiro- [17H-dicyclopropa-6,7:15,16]cyclopenta [a]phenanthrene-17,2'(5H)-furan]-3,5'(2H)-dione) | |
| Identifiers | |
| CAS number | |
| ATC code | G03 |
| PubChem | |
| Chemical data | |
| Formula | C24H30O3 |
| Mol. mass | 366.493 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 76% |
| Protein binding | 97% |
| Metabolism | Hepatic, minor (CYP3A4-mediated) |
| Half life | 30 hours |
| Excretion | Renal and fecal |
| Therapeutic considerations | |
| Pregnancy cat. |
X(US) |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Drospirenone | |
|
Articles | |
|---|---|
|
Most recent articles on Drospirenone Most cited articles on Drospirenone | |
|
Media | |
|
Powerpoint slides on Drospirenone | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Drospirenone at Clinical Trials.gov Clinical Trials on Drospirenone at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Drospirenone
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Drospirenone Discussion groups on Drospirenone Patient Handouts on Drospirenone Directions to Hospitals Treating Drospirenone Risk calculators and risk factors for Drospirenone
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Drospirenone | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Drospirenone is a synthetic progestin that is an analog to spironolactone. Its molecular weight is 366.5 and its molecular formula is C24H30O3.
Properties and uses
The compound is part of certain birth control formulations. Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic. With its activities similar to spironolactone it may lead to less water retention and breast tenderness and improved skin appearance (less acne).
Drospirenone is taken orally with about 76% bioavailability. It is not bound by sex hormone binding globulin or corticosteroid binding globulin, but by other serum proteins. Metabolites have not been shown to be biologically active, show up in urine and feces, and are essentially completely excreted within 10 days.
The compound is part of certain newer oral contraceptive formulations:
- Yasmin® contains 3 mg drospirenone and 30 mcg ethinylestradiol per tablet. It is indicated for the prevention of pregnancy in women who elect an oral contraceptive.
- Yaz® contains 3 mg drospirenone and 20 mcg ethinylestradiol per tablet and is given for 24/4 days with the same indications.
It has also been formulated in medication to manage menopausal symptoms using 0.5 mg drsp and 1 mg estradiol per day by oral application. This medication was introduced in the USA in 2007 as Angeliq®.
Drospirenone, which can potentially cause hyperkalemia in high-risk patients, is comparable to a 25mg dose of spironolactone.
The medication is contraindicated in patients with hepatic dysfunction, renal insufficiency, adrenal insufficiency, or in whom the use of oral contraceptives is contraindicated, such as smokers and patients with a history of DVT, stroke, or other blood clots. Because of the anti-mineralocorticoid effects care needs to be exercised when other drugs that may increase potassium levels are taken. Such medications include ACE inhibitors, angiotensin-II receptor agonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDs.
See also
- Progestins
- Combined oral contraceptive pill
- Oral contraceptive formulations
- Hormone replacement therapy
References
- Krattenmacher R (2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception 62 (1): 29-38. PMID 11024226.
- Yasmin product information
- Angeliq product information
External links
de:Drospirenon
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
